Drug Trial Radar · NCT01215851
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
Last checked: Nov 19, 2026Latest source record: Feb 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Oct 2010
Primary completion
May 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- Global Alliance for TB Drug DevelopmentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 7, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral administration of TMC207 alone, TMC207 with pyrazinamide, TMC207 with PA-824, PA-824 with pyrazinamide and PA-824 with moxifloxacin and pyrazinamide, as determined by the rate of change of log CFU in sputum over the time period Day 0-14 in participants with smear positive pulmonary tuberculosis (TB). A control group will receive standard treatment.
Conditions
- Pulmonary Tuberculosis
Interventions
PA-824Drug
200 mg tablet, once daily for 14 days
PyrazinamideDrug
Dosed by Weight
TMC207Drug
TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
RifafourDrug
Rifafour e-275
MoxifloxacinDrug
moxifloxacin 400 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Bactericidal Activity (EBA) Measured as the Mean Rate of Change of log10 Colony Forming Units (CFU) of M. Tuberculosis Per ml Sputum on Solid Medium Over Time (Days 0-14).Time frame: 14 consecutive days of treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Centre for Tuberculosis Research Innovation, UCT Lung Institute
Cape Town, South Africa
Task Applied Science, Karl Bremer Hospital
Cape Town, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.